natgillin/translations-raw huggingface dataset:
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Rizik od hiperkalemije se povećava u slučaju kombinacije s drugim lijekovima koji također mogu izazvati hiperkalemiju (nadomjesci soli koji sadrže kalij, diuretici koji štede kalij, ACE-inhibitori, antagonisti receptora angiotenzina II, nesteroidni protuupalni lijekovi (NSAIL, uključujući selektivne COX-2 inhibitore), heparin, imunosupresivi (ciklosporin ili takrolimus) i trimetoprim).
Anaphylactic reaction , hypersensitivity Metabolism and nutrition disorders Uncommon:
Anafilaktička reakcija, preosjetljivost Poremećaji metabolizma i prehrane Manje često:
What Telmisartan Actavis looks like and contents of the pack 20 mg tablets are white, round, flat with logo T on one side
Kako Telmisartan Actavis izgleda i sadržaj pakiranja Tablete od 20 mg su bijele, okrugle, plosnate s oznakom T na jednoj strani.
Al/Al blisters: Pack sizes: 14, 28, 30, 56, 84, 90, 98 or 100 tablets.
Veličine pakiranja: 14, 28, 30, 56, 84, 90, 98 ili 100 tableta.
Telmisartan Actavis tablets are used to treat essential hypertension (high blood pressure) in adults.
Telmisartan Actavis tablete se primjenjuju u liječenju esencijalne hipertenzije (visoki krvni tlak) u odraslih osoba. „Esencijalna“ znači da visoki krvni tlak nije izazvan niti jednim drugim uzrokom.
Eosinophilia , thrombocytopenia
Anemija Eozinofilija, trombocitopenija
What Telmisartan Actavis looks like and contents of the pack 40 mg tablets are white, oval, biconvex, with a break line and logo T on one side.
Kako Telmisartan Actavis izgleda i sadržaj pakiranja Tablete od 40 mg su bijele, ovalne, bikonveksne s razdjelnom linijom s oznakom T na jednoj strani.
may lead to excessive loss of body water and low blood pressure (hypotension).
Telmisartan Actavis, mogu dovesti do prekomjernog gubitka vode u tijelu te niskog krvnog tlaka (hipotenzija).
Clinical efficacy and safety
Klinička djelotvornost i sigurnost Liječenje esencijalne hipertenzije
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95% CI 0.76-1.00, p = 0.048)], There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95% CI 0.85-1.24).
Dokazana je korist liječenja telmisartanom u usporedbi s placebom u prethodno određenom sekundarnom složenom ishodu od kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,87 (95% CI 0,76 - 1,00, p = 0,048)].
- Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain 'water tablets'), ACE inhibitors (angiotensinconverting enzyme inhibitors, to treat high blood pressure), angiotensin II receptor antagonists (to treat high blood pressure), NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin (a medicine for thinning the blood), immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
diuretici koji štede kalij (određene tablete za mokrenje), ACE-inhibitori (inhibitori angiotenzin konvertirajućeg enzima za liječenje visokog krvnog tlaka), antagonisti receptora angiotenzina II (za liječenje visokog krvnog tlaka), NSAIL (nesteroidni protuupalni lijekovi, npr. aspirin ili ibuprofen), heparin (lijek za razrjeđivanje krvi), imunosupresivi (npr. ciklosporin ili takrolimus) te antibiotik trimetoprim.
Anaphylactic reaction, hypersensitivity Metabolism and nutrition disorders Uncommon:
Anafilaktička reakcija, preosjetljivost Poremećaji metabolizma i prehrane
Interstitial lung disease4
Dispneja, kašalj Bolest plućnog intersticija4
Potassium sparing diuretics or potassium supplements Angiotensin II receptor antagonists such as telmisartan attenuate diuretic induced potassium loss.
Antagonisti receptora angiotenzina II, kao što je telmisartan, ublažavaju gubitak kalija induciranog diureticima.
INFORMATION IN BRAILLE Telmisartan Actavis 40 mg
16. PODACI NA BRAILLEOVOM PISMU Telmisartan Actavis 40 mg
INFORMATION IN BRAILLE Telmisartan Actavis 20 mg
16. PODACI NA BRAILLEOVOM PISMU Telmisartan Actavis 20 mg
Reduction of cardiovascular morbidity in adults with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or - type 2 diabetes mellitus with documented target organ damage
Smanjenje kardiovaskularnog morbiditeta u odraslih osoba s: - manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca,
INFORMATION IN BRAILLE Telmisartan Actavis 80 mg
16. PODACI NA BRAILLEOVOM PISMU Telmisartan Actavis 80 mg
Hypotension2, orthostatic hypotension Respiratory, thoracic and mediastinal disorders Uncommon:
Hipotenzija 2, ortostatska hipotenzija
In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70% vs. 0.49% [RR 1.43 (95% confidence interval 1.00- 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33%) vs. patients taking placebo (0.16%) [RR 2.07 (95% confidence interval 1.14 3.76)].
1,00 - 2,06)]; incidencija smrtnih slučajeva od sepse bila je povećana za bolesnike koji su uzimali telmisartan (0,33%) u odnosu na bolesnike koji su uzimali placebo (0,16%) [RR 2,07 (95% interval pouzdanosti 1,14 - 3,76)].
If you take more Telmisartan Actavis than you should It is important to keep to the dose as prescribed by your doctor.
Važno je da se pridržavate doze koju Vam je propisao liječnik.
Each tablet contains 40 mg telmisartan.
Jedna tableta sadrži 40 mg telmisartana.
In cases where the target blood pressure is not achieved, the dose of telmisartan can be increased to a maximum of 80 mg once daily.
doza telmisartana može se povisiti na maksimalno 80 mg jednom dnevno.
Each tablet contains 20 mg telmisartan.
Jedna tableta sadrži 20 mg telmisartana.
6.5 Nature and contents of container
6.5 Vrsta i sadržaj spremnika Al/Al blisteri:
Each tablet contains 80 mg telmisartan.
Jedna tableta sadrži 80 mg telmisartana.
itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood.
ubrzani otkucaji srca (tahikardija), suhoća usta, nadražaj želuca, poremećaj osjeta okusa (disgeuzija), abnormalna funkcija jetre (vjerojatnost da će iskusiti ovu nuspojavu, veća je za bolesnike iz Japana), brzo oticanje kože i sluznice koji mogu dovesti do smrtnog ishoda (angioedem također sa smrtnim ishodom), ekcem (poremećaj kože), crvenilo kože, koprivnjača (urtikarija), težak osip od lijeka, bol u zglobovima (artralgija), bol u udovima, bol tetiva, simptomi nalik gripi, snižen hemoglobin (krvni protein), povišena razina mokraćne kiseline, povišeni jetreni enzimi ili kreatin fosfokinaza u krvi.
Magnesium stearate Croscarmellose sodium Mannitol
6.1 Popis pomoćnih tvari magnezijev stearat karmelozanatrij, umrežena manitol povidon pelete kalijevog hidroksida
Somnolence
Vrtoglavica
Before considering the concomitant use of medicinal products that affect the renin-angiotensinaldosterone system, the benefit risk ratio should be evaluated.
Prije razmatranja istodobne primjene lijekova koji utječu na sustav renin-angiotenzin-aldosteron,
Immune system disorders Rare:
Poremećaji imunološkog sustava
Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Infekcije mokraćnih puteva, infekcije gornjih dišnih puteva (npr. grlobolja, upala sinusa, obična prehlada), nedostatak crvenih krvnih stanica (anemija), visoke razine kalija, otežano spavanje, osjećaj tuge (depresija), nesvjestica (sinkopa), osjećaj vrtnje (vrtoglavica), usporen rad srca (bradikardija), nizak krvni tlak (hipotenzija) u korisnika liječenih zbog visokog krvnog tlaka, omaglica pri ustajanju
NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 40 mg tablets
NAZIV LIJEKA Telmisartan Actavis 40 mg tablete
NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 40 mg tablets telmisartan
NAZIV LIJEKA Telmisartan Actavis 40 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 80 mg tablets telmisartan
NAZIV LIJEKA Telmisartan Actavis 80 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 20 mg tablets
NAZIV LIJEKA Telmisartan Actavis 20 mg tablete
PHARMACEUTICAL FORM Tablet
14. NAČIN IZDAVANJA LIJEKA
Blood and the lymphatic system disorders Uncommon:
Poremećaji krvi i limfnog sustava
NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 20 mg tablets telmisartan
NAZIV LIJEKA Telmisartan Actavis 20 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 80 mg tablets
NAZIV LIJEKA Telmisartan Actavis 80 mg tablete
6.6 Special precautions for disposal and other handling
6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Nema posebnih zahtjeva.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg telmisartan.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 80 mg telmisartana.
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5% CI 0.901.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
(97,5% CI 0,90 - 1,08), p (neinferiornost) = 0,0004], u primarnom ishodu referentnog ispitivanja HOPE (The Heart Outcomes
MARKETING AUTHORISATION NUMBER(S) EU/1/10/639/029 (30 tablets container) EU/1/10/639/030 (250 tablets container)
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/639/029 (spremnik s 30 tableta) EU/1/10/639/030 (spremnik s 250 tableta)
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg telmisartan.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 40 mg telmisartana.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg telmisartan.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 20 mg telmisartana.
Most cases of hepatic function abnormal / liver disorder from post-marketing experience occurred in patients in Japan, who are more likely to experience these adverse reactions.
abnormalna funkcija jetre (vjerojatnost da će iskusiti ovu nuspojavu, veća je za bolesnike iz Japana),
MARKETING AUTHORISATION NUMBER(S) EU/1/10/639/019 (30 tablets container) EU/1/10/639/020 (250 tablets container)
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/639/019 (spremnik s 30 tableta) EU/1/10/639/020 (spremnik s 250 tableta)
MARKETING AUTHORISATION NUMBER(S) EU/1/10/639/009 (30 tablets container) EU/1/10/639/010 (250 tablets container)
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/639/009 (spremnik s 30 tableta) EU/1/10/639/010 (spremnik s 250 tableta)
Tachycardia
Bradikardija Tahikardija
Take Telmisartan Actavis every day for as long as your doctor prescribes it in order to keep your blood pressure controlled.
Ako prestanete uzimati Telmisartan Actavis Kako biste držali svoj tlak pod kontrolom, uzimajte Telmisartan Actavis svaki dan toliko dugo koliko
EU/1/10/639/001 (14 tablets blister) EU/1/10/639/002 (28 tablets blister) EU/1/10/639/003 (30 tablets blister) EU/1/10/639/004 (56 tablets blister) EU/1/10/639/005 (84 tablets blister) EU/1/10/639/006 (90 tablets blister) EU/1/10/639/007 (98 tablets blister) EU/1/10/639/008 (100 tablets blister)
EU/1/10/639/005 (blister s 84 tablete) EU/1/10/639/006 (blister s 90 tableta) EU/1/10/639/007 (blister s 98 tableta) EU/1/10/639/008 (blister sa 100 tableta)
Common side effects (may affect up to 1 in 10 people): Low blood pressure (hypotension) in users treated for reduction of cardiovascular events.
Nizak krvni tlak (hipotenzija) u bolesnika liječenih zbog smanjivanja kardiovaskularnih događaja.
EU/1/10/639/011 (14 tablets blister) EU/1/10/639/012 (28 tablets blister) EU/1/10/639/013 (30 tablets blister) EU/1/10/639/014 (56 tablets blister) EU/1/10/639/015 (84 tablets blister) EU/1/10/639/016 (90 tablets blister) EU/1/10/639/017 (98 tablets blister) EU/1/10/639/018 (100 tablets blister)
EU/1/10/639/015 (blister s 84 tablete) EU/1/10/639/016 (blister s 90 tableta) EU/1/10/639/017 (blister s 98 tableta) EU/1/10/639/018 (blister sa 100 tableta)
EU/1/10/639/021 (14 tablets blister) EU/1/10/639/022 (28 tablets blister) EU/1/10/639/023 (30 tablets blister) EU/1/10/639/024 (56 tablets blister) EU/1/10/639/025 (84 tablets blister) EU/1/10/639/026 (90 tablets blister) EU/1/10/639/027 (98 tablets blister) EU/1/10/639/028 (100 tablets blister)
EU/1/10/639/025 (blister s 84 tablete) EU/1/10/639/026 (blister s 90 tableta) EU/1/10/639/027 (blister s 98 tableta) EU/1/10/639/028 (blister sa 100 tableta)
Cardiac disorders Uncommon:
Kardiovaskularna prevencija ONTARGET ispitivanje (eng.
Renal impairment including acute renal failure General disorders and administration site conditions Uncommon: Rare:
Opći poremećaji i reakcije na mjestu primjene Manje često:
Teл.
(tahikardija).
Back pain (e.g. sciatica), muscle spasms, myalgia Arthralgia, pain in extremity, tendor pain (tendinitis like symptoms)
Artralgija, bol u ekstremitetima, bol tetiva (simptomi poput tendinitisa)
EU/1/10/639/001 (14 tablets blister) EU/1/10/639/002 (28 tablets blister) EU/1/10/639/003 (30 tablets blister) EU/1/10/639/004 (56 tablets blister) EU/1/10/639/005 (84 tablets blister) EU/1/10/639/006 (90 tablets blister) EU/1/10/639/007 (98 tablets blister) EU/1/10/639/008 (100 tablets blister) EU/1/10/639/009 (30 tablets container) EU/1/10/639/010 (250 tablets container)
EU/1/10/639/001 (blister s 14 tableta) EU/1/10/639/002 (blister s 28 tableta) EU/1/10/639/003 (blister s 30 tableta) EU/1/10/639/004 (blister s 56 tableta)
Inventedname Strength Pharmaceutical Form
(Zaštićeno) ime Jačina Farmaceutski oblik
EU number
Brojevi (EU) odobrenja za stavljanje lijeka u promet
If you need more information about your animal's medical condition or treatment, contact your veterinarian.
Ako trebate više informacija o zdravstvenom stanju ili liječenje svoje životinje, obratite se veterinaru.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Cjepiva djeluju „učeći” imunosni sustav (prirodna obrana tijela) kako se obraniti od bolesti.
They included young and adult cats of various breeds, but not young kittens.
Ispitivanja su obuhvatila mlade i odrasle mačke različitih pasmina, ali ne i mlade mačiće.
This is a summary of the European public assessment report.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije.
The antibodies will help to protect against the diseases caused by these viruses.
Protutijela pomažu u zaštiti od bolesti koje uzrokuju ti virusi.
The first injection should be given in kittens aged at least eight weeks, with a second injection three to four weeks later.
Prvu injekciju treba dati mačićima u dobi od najmanje osam tjedana, a drugu injekciju tri do četiri tjedna kasnije.
The cat should be revaccinated for all components one year after the first vaccination course, then every three years.
Potrebno je provesti revakcinaciju mačke za sve komponente godinu dana nakon prvog cijepljenja, a zatim svake tri godine.
When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.
Ako u budućnosti bude izložena nekom od tih virusa, mačka se neće zaraziti ili će imati mnogo blažu infekciju.
Information on the prescription status of this product may be found on the label/outer package.
Informacije o tome je li za ovaj proizvod potreban recept možete naći na etiketi/vanjskom pakiranju.
The European Commission granted a marketing authorisation valid throughout the European Union for Purevax RC on 23 February 2005.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Purevax RC na snazi u Europskoj uniji od 23. veljače 2005.
If the kitten has high levels of antibodies received from the mother in the womb and in the milk, the first vaccination should be delayed until 12 weeks of age.
Ako mačić ima visoke razine majčinih protutijela prenesenih u maternici i mlijekom, prvo cijepljenje trebalo bi odgoditi do dobi od 12 tjedana.
Purevax RC should not be used in pregnant cats.
Purevax RC ne smije se primjenjivati u gravidnih mačaka.
The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine.
Glavna mjera djelotvornosti bila je razina protutijela u krvi na viruse iz cjepiva.
Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days.
U mačaka se povremeno može javiti privremena apatija (gubitak interesa za okolinu) i anoreksija (gubitak apetita), kao i hipertermija (povišena tjelesna temperatura) koja traje jedan ili dva dana.
The vaccine helps to reduce the symptoms of the diseases and also helps to reduce viral excretion in case of calicivirus infection for one year after vaccination.
Cjepivo pomaže u ublažavanju simptoma bolesti, kao i u smanjenju ekskrecije virusa u slučaju infekcije kalicivirusom tijekom jedne godine nakon cijepljenja.
There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks.
Može se pojaviti i lokalna reakcija na mjestu injekcije u obliku lagane boli na dodir, svrbeža ili edema (otok), koja nestaje unutar jednog ili dva tjedna.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘foreign' and makes antibodies against them.
Kada mačka primi cjepivo, imunosni sustav prepoznaje oslabljene ili umrtvljene viruse kao „strana tijela” te protiv njih proizvodi protutijela.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RC exceed the risks for the approved indications and recommended that Purevax RC be given a marketing authorisation.
Odbor za veterinarsko-medicinske proizvode (CVMP) zaključio je da koristi od VMP-a Purevax RC nadmašuju rizike za odobrene indikacije te je preporučio davanje odobrenja za stavljanje VMP-a Purevax RC u promet.
Purevax RC is used to vaccinate cats from the age of 8 weeks against:
Purevax RC koristi se za cijepljenje mačaka starijih od osam tjedana protiv:
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses.
Nakon cijepljenja imunosni sustav može brže proizvoditi protutijela ako u budućnosti bude izložen stvarnim virusima.
• inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains).
• inaktivirane (umrtvljene) antigene kalicivirusa (sojeve FCV 431 i G1).
In case of accidental self-injection medical advice should be sought immediately and the package leaflet or the label shown to the doctor.
U slučaju nehotičnog samoinjektiranja treba odmah potražiti liječnički savjet te pokazati uputu o proizvodu ili etiketu.
Purevax RC is a veterinary vaccine that contains:
Purevax RC je veterinarsko cjepivo koje sadrži:
The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Omjer koristi i rizika možete pronaći u modulu znanstvene rasprave ovog EPAR-a.
The effectiveness of Purevax RC has been studied in several trials in laboratory conditions where cats were vaccinated and infected with herpesvirus and calicivirus.
Djelotvornost VMP-a Purevax RC ispitivana je u nekoliko ispitivanja u laboratorijskim uvjetima, u okviru kojih su mačke cijepljene i potom zaražene herpesvirusom i kalicivirusom.
In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above.
U laboratorijskim uvjetima dokazano je da VMP Purevax RC pruža zaštitu od prethodno navedenih bolesti.
Purevax RC is available as a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Purevax RC dostupan je kao liofilizat (smrzavanjem osušen pelet) i otapalo od kojih se priprema suspenzija za injekciju.
Purevax RC contains small amounts of weakened or killed viruses that cause feline rhinotracheitis and calicivirosis.
Purevax RC sadrži male količine oslabljenih ili umrtvljenih virusa koji uzrokuju rinotraheitis i kalicivirozu mačaka.
In the field, the studies of Purevax RC looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination.
U ispitivanjima VMP-a Purevax RC na terenu razmatrao se osnovni raspored cijepljenja (dvije injekcije u razmaku od tri do četiri tjedna) te docjepljivanje.
• attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain),
• atenuirani (oslabljeni) herpesvirus rinotraheitisa mačaka (soj FHV F2),
Purevax RC is a vaccine.
Purevax RC je cjepivo.
• feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus).
• kaliciviroze mačaka (bolest nalik na gripu s upalom usta uzrokovana kalicivirusom).
Feline viral rhinotracheitis (live attenuated) and feline calicivirosis (inactivated) vaccine
Cjepivo protiv virusnog rinotraheitisa (živo atenuirano) i kaliciviroze mačaka (inaktivirano)
What is the risk associated with Purevax RC?
Koji su rizici povezani s VMP-om Purevax RC?
For a full list of the side-effects reported with Purevax RC, see the package leaflet.
Potpuni popis svih nuspojava zabilježenih pri primjeni VMP-a Purevax RC potražite u uputi o VMP-u.
Why has Purevax RC been approved?
Zašto je Purevax RC odobren?
In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus and calicivirus infection.
U terenskom ispitivanju osnovnog cijepljenja zabilježen je porast protutijela na herpesvirus rinotraheitisa i kalicivirus u mačaka.
What is Purevax RC?
Što je Purevax RC?
Other information about Purevax RC:
Ostale informacije o VMP-u Purevax RC
What is Purevax RC used for?
Za što se Purevax RC koristi?
• feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus),
• virusnog rinotraheitisa mačaka (bolest nalik na gripu uzrokovana herpesvirusom),
What benefit has Purevax RC shown during the studies?
Koje su koristi VMP-a Purevax RC utvrđene u ispitivanjima?
How does Purevax RC work?
Kako djeluje Purevax RC?